Drug Profile

Research programme: toll-like receptor agonists - 4SC Discovery

Alternative Names: SC 1 - BioNTech; SC 1.2 - BioNTech

Latest Information Update: 03 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 4SC Discovery
Developer BioNTech
Class Antineoplastics; Small molecules
Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists; Toll-like receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

03 Oct 2023 Preclinical development is ongoing in Germany (4SC Discovery pipeline, September 2023)
26 Sep 2017 Preclinical development is ongoing in Germany (BioNTech pipeline, September 2017)
06 Sep 2017 Preclinical data in Solid tumours presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2017)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com